SecBot SecBot
COURT-RULING ·Filed Aug 25, 2026

TEVA

TEVA PHARMACEUTICAL INDUSTRIES LTD
NEUTRAL
Impact 2/10
Horizonimmediate Processed2mo ago CourtCourt Ruling · govinfo.gov
Court ruling (district)
Actionable Insight • Neutral

This ruling has no material impact on Teva's stock. The underlying EpiPen antitrust MDL continues, but today's order is a routine discovery dispute over a non-party law firm's search terms and redactions. Monitor for substantive rulings on class certification, summary judgment, or trial, which would carry real financial exposure.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$37.92
T+0 close · Aug 26, 2026 · via day close
Latest settled
+6.07%
T+20 · $40.22 · next T+60 in 2d
Vs SPY
+5.67%
α at T+20
Latest observation
+21.25%
T+57 · FF3 residual α
  1. T+0 · Aug 26 $37.92entry
  2. T+1 · 3mo ago −0.79%α −1.45% · $37.62
  3. T+5 · 3mo ago −1.13%α −1.01% · $37.49
  4. T+20 · 8w ago +6.07%α +5.67% · $40.22
  5. T+57 · todayOpen
  6. T+60 · in 2d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

A federal magistrate judge in Kansas granted in part and denied in part a motion to compel non-party law firm Goodwin Procter to re-run document searches in the long-running EpiPen antitrust MDL against Teva. The court denied plaintiffs' request for additional search terms as untimely and insufficiently justified, but ordered Goodwin to submit two redacted email strings for in camera review. This is a routine discovery dispute with no material financial exposure or business impact on Teva, the ruling does not address liability, damages, or any substantive claim in the underlying antitrust case.

Court Ruling Details

Ruling Date
Aug 25, 2026
Court
United States District Court for the District of Kansas
Court Level
District
Judge
Teresa J. James
Case Type
antitrust
Ruling Type
procedural
Outcome
PARTIAL: mixed ruling, some claims won/lost
Precedent Risk
LOW

Key Facts

  • Ruling is a discovery dispute over non-party law firm Goodwin Procter's document production in the EpiPen antitrust MDL (Case 2:22-cv-02501-DDC-TJJ).
  • Court denied plaintiffs' request to compel Goodwin to run additional search terms, finding the motion untimely and the burden outweighed the likely benefit.
  • Court granted in part plaintiffs' request regarding two redacted email strings, ordering Goodwin to submit unredacted versions for in camera review.
  • No damages, injunction, or liability finding was made against Teva, the ruling concerns only procedural discovery obligations of a non-party law firm.
  • The underlying case is a multi-district antitrust litigation regarding EpiPen pricing, but this specific ruling has no financial exposure for Teva.

Financial Impact

No financial impact, this is a procedural discovery ruling with no damages, penalties, or business restrictions imposed on Teva.

Risk Factors

  • The underlying EpiPen antitrust MDL could eventually result in material damages or injunctive relief against Teva, but today's ruling does not change that risk profile.
  • If the in camera review of the two email strings reveals discoverable material, it could lead to further discovery disputes, but the scope is narrow.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 court opinion.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-9d441e92f6-TEVA

Track record

61 reports on TEVA

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 15 of 17 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $42.57 −1.37% settles Feb 12
  2. Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
  3. Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
  4. Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $42.57 −2.47% settles Feb 10
  5. Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $42.57 −1.55% settles Feb 9
  6. Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
  7. Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
  8. Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
  9. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
  10. Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $42.57 −0.09% settles Feb 4
Showing 10 of 61

US Market Status

Market Closed · Opens in 9h 21m

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ Court Ruling · govinfo.gov Report published Aug 26, 2026